The new workflow, described in Physiological Reports, measures five key endpoints simultaneously: the number of myonuclei per muscle cell, the number of Pax7-positive satellite cells per cell, the cross-sectional area of each fiber, the perimeter of each fiber, and the fiber’s type, classifying it as slow-twitch type I or fast-twitch type II. According to the authors, this is the first published pipeline to combine all five measurements in a single workflow compatible with widely available widefield microscopy, rather than requiring specialized imaging platforms. Each of these endpoints carries real biological weight. Satellite cells are the resident stem cells of skeletal muscle, and their expansion and integration into fibers as new myonuclei underpins theories such as the myonuclear domain hypothesis, which holds that each nucleus governs a finite volume of cytoplasm. Emerging evidence even suggests the domain may track fiber perimeter more closely than cross-sectional area, making accurate perimeter measurement newly important.

The pipeline begins before any computation, with careful tissue handling and staining. Human biopsies were taken from the vastus lateralis, the lateral thigh muscle that is a standard site in exercise physiology studies. Tissue was embedded in optimal cutting temperature compound, flash-frozen in liquid-nitrogen-cooled isopentane, and sectioned at seven micrometers on a cryostat. Immunohistochemistry then labeled three targets: laminin, a protein that outlines the sarcolemma surrounding each fiber; type I myosin heavy chain, which marks slow fibers; and Pax7, the canonical marker of quiescent and activated satellite cells. Slides were imaged at twenty-fold magnification on a Leica widefield microscope across four channels—DAPI for all nuclei, green fluorescence for Pax7, yellow for myosin heavy chain I, and far-red for laminin—producing the raw material for analysis.

A crucial early stage is manual image cleaning in Fiji/ImageJ. Rather than treating every pixel as trustworthy data, the protocol calls for brightness and contrast optimization on each channel, followed by manual removal of artifacts such as tissue folds, blood vessels, blurred or overlapping laminin signal, and out-of-focus nuclei. The authors argue this step, though the most time-consuming part of the workflow, is essential: it strips out the noise that would otherwise generate false positives downstream and brings the analyzed regions into line with what a careful human analyst would measure. Cleaned images are then exported with a strict naming convention that encodes subject, timepoint, leg, and set, enabling fully automated batch processing.

The computational core pairs two open-source tools. CellProfiler, the modular image-analysis platform maintained at the Broad Institute, orchestrates segmentation and measurement, while Cellpose, a machine-learning model developed at HHMI’s Janelia Research Campus, performs deep-learning-based detection of cellular boundaries. Fiber segmentation uses Cellpose’s cyto2 model on the laminin channel to trace sarcolemmal borders. Nuclear segmentation is trickier, because muscle cross-sections contain nuclei from many cell types, and the default Cellpose nuclei model is highly sensitive. The pipeline handles this with an iterative subtraction strategy: a Gaussian filter smooths the DAPI signal, an initial Cellpose run identifies candidate nuclei, background intensity statistics are computed, the seventeenth percentile of pixel intensity is subtracted to suppress non-specific fluorescence, and a refined second run produces the final nuclear masks.

Notably, deep learning proved less suitable for the rarest target. Pax7-positive satellite cells are sparse—on average only about one per ten fibers in the validation dataset—and their signal is faint against the sarcoplasmic background. For these, the pipeline falls back on CellProfiler’s classical IdentifyPrimaryObjects module, using Otsu thresholding with size, circularity, and intensity filters tuned to the amplified Pax7 signal. The authors note the modular design means this component could be swapped to detect other sparse cell populations; they have already adapted the same pipeline to identify macrophages and atrophied fibers in an elderly clinical cohort.

A custom Python script built on OpenCV, pandas, and NumPy then fuses the separate segmentation masks into a single biological dataset. Each fiber mask is decomposed by its unique grayscale label, and every nucleus or satellite cell is assigned to the fiber with which it shares the greatest bitwise pixel overlap—a ‘greatest overlap’ rule that resolves objects straddling two fibers. Fiber area and perimeter are computed in physical units using a pixel-to-micron scaling factor, and fiber type is assigned automatically by measuring mean type I myosin heavy chain fluorescence within each fiber mask after rolling-ball background subtraction. The intensity threshold separating type I from type II fibers, set at a pixel value of twenty, was derived empirically from an analysis of 3,722 cells across twelve human biopsies. Output is a unified Excel workbook listing fiber ID, area, perimeter, nuclear count, satellite cell count, and typing for every cell, alongside diagnostic overlay images that allow researchers to audit the automated calls visually.

Validation against traditional manual analysis is where the pipeline earns its credentials. The team compared both methods head-to-head on 310 matched cells from a human biopsy. For myonuclei per cell, manual counting averaged 2.471 nuclei versus 2.474 for the pipeline, a difference of just -0.003 nuclei, with no statistically significant difference by paired t-test. Satellite cell counts likewise agreed, averaging 0.110 manually versus 0.119 automatically. Fiber typing was the strongest performer: the pipeline classified 49 type I and 261 type II fibers against the manual count of 48 and 262, with a correlation of r = 0.939 between methods. Cross-sectional area and perimeter correlated even more highly, at r = 0.959 and r = 0.935 respectively, though with systematic offsets that the authors explain candidly.

Those offsets trace to boundary conventions rather than measurement failure. Manual outlines were drawn with a ten-pixel brush slightly inside the laminin border, while the automated segmentation places its one-pixel outline on or marginally outside it. Because area and perimeter are computed from within the drawn boundary, this small difference inflates automated values—the pipeline averaged 3,532 versus 3,005 square micrometers for area, and 264 versus 249 micrometers for perimeter. Similar discrepancies between manual and automated fiber outlines have been reported before, and the authors stress that users simply need to apply consistent methodology. Other limitations include the mandatory image-cleaning step, strict file-naming requirements, and occasional detection failures on very sparse or dim fields of view, for which the authors suggest alternative Cellpose detection modes or the newer Cellpose3.

The practical payoff is throughput. Published power calculations indicate that comparisons of satellite cells per fiber require at least fifty type I and seventy-five type II fibers, and many labs have settled on a minimum of 150 cells per biopsy as a working threshold. A single human biopsy can yield well over a thousand fibers, and the new pipeline can process all of them, dramatically increasing sample representation while reducing both analysis time and operator dependence. Every cell receives a unique identifier, every segmentation decision is saved as a reviewable overlay, and the modular CellProfiler architecture invites adaptation to new antibodies, tissues, and imaging conditions. As interest grows in satellite cell dynamics across the human lifespan—from athletic performance to sarcopenia and rehabilitation—the authors argue this workflow offers muscle biologists a scalable, transparent, and reproducible foundation for turning microscope images into meaningful numbers.

Subject of Research: A semi-automated microscopy pipeline for quantifying satellite cells, myonuclei, and muscle fiber morphology in human skeletal muscle cross-sections

Article Title: A semi‐automated pipeline for quantitation of Pax7+, myonuclei, and cross‐sectional area by fiber type

Article References: Megowan, H. G., Luu, M., Shuaib, A., Augienello, K. B., Fries, A. C., Searcy, J., & Dreyer, H. C. (2026). A semi‐automated pipeline for quantitation of Pax7+, myonuclei, and cross‐sectional area by fiber type. Physiological Reports, 14(18), Article e71097. https://doi.org/10.14814/phy2.71097

Image Credits: AI Generated

DOI: 10.14814/phy2.71097

Keywords: skeletal muscle, satellite cells, Pax7, myonuclei, cross-sectional area, fiber type, image analysis, CellProfiler, Cellpose, immunohistochemistry, muscle biology, widefield microscopy

Centronuclear myopathies are a group of rare inherited disorders defined by progressive muscle wasting and weakness, named for the abnormal positioning of nuclei at the centre of muscle fibres rather than at their periphery. The most common autosomal dominant form is caused by mutations in the DNM2 gene, which encodes dynamin 2, a GTPase enzyme involved in membrane fission, intracellular trafficking and organelle morphology. Roughly 40 different heterozygous DNM2 mutations have been linked to the disease, which accounts for approximately 15 percent of all centronuclear myopathy cases. Severity ranges broadly, from mild late-onset weakness to severe neonatal forms, and no curative therapy currently exists.

In a study published in the Journal of Cachexia, Sarcopenia and Muscle, a research team used the KI-Dnm2 R465W/+ mouse model, which carries a disease-causing mutation analogous to those found in patients, to test whether inhibiting myostatin could counteract the muscle deterioration characteristic of the disease. Myostatin, also known as growth differentiation factor 8, is widely regarded as the master negative regulator of skeletal muscle mass throughout development and adult life. It signals through the activin type IIB receptor, activating the SMAD2/3 pathway, which suppresses the proliferation and differentiation of muscle precursor cells, represses the IGF1-Akt-mTOR anabolic pathway, downregulates muscle-specific genes and promotes E3 ubiquitin ligases involved in protein degradation.

The researchers first mapped the natural course of the disease in these mice using longitudinal magnetic resonance imaging, repeated at 1, 2 and 8 months of age with a high-field 7-Tesla system. Although the knockin mice were viable and grew normally in body size, their leg muscle cross-sectional area lagged dramatically behind healthy littermates. Between 1 and 2 months of age, a critical postnatal growth window, healthy mice expanded their leg muscle cross-sectional area by 1.5-fold, while the mutant mice managed only a 1.2-fold increase. Functional testing revealed that the trouble began even earlier: impaired motor coordination and reduced grip strength were already detectable at 1 month, before measurable muscle growth failure appeared, and histological analysis of the tibialis anterior muscle showed more than 20 percent of fibres displaying the hallmark central NADH-TR staining pattern of the disease at 2 months.

Digging into the molecular roots of this growth failure, the team found a coordinated disruption of multiple homeostatic systems. The number of Pax7-positive satellite cells, the stem-like reservoir that fuses with growing fibres to supply new myonuclei, was significantly reduced, along with MyoD expression, indicating defective myonuclear accretion. At the same time, the translational repressor Eif4ebp1 was upregulated, suggesting suppressed protein synthesis, while FOXO3 and its downstream E3 ligase targets MuRF1, Atrogin-1 and Musa1 were elevated, pointing to accelerated protein breakdown. Autophagy-related transcripts such as Bnip3 and Map1lc3b were paradoxically reduced while P62 and LC3B-I protein accumulated, a signature of impaired autophagic flux. Together, these findings paint centronuclear myopathy not as a single broken pathway but as a global collapse of muscle protein and nuclear homeostasis.

To test whether myostatin was a viable therapeutic target, the researchers crossed the mutant mice with a myostatin knockout line, producing double-mutant animals completely lacking functional myostatin. The results were dramatic. The double-mutant mice gained substantially more body weight, and the mass of the tibialis anterior, quadriceps, extensor digitorum longus and soleus muscles far exceeded even healthy wild-type levels. Critically, grip strength and rotarod performance, which were significantly impaired in the myopathy mice, were fully restored to normal. Because myostatin is absent from embryogenesis onward in these animals, lifelong suppression appears to be integrated into developmental muscle growth programs, including enhanced satellite cell activation and myoblast proliferation, producing stable structural and functional benefits.

Genetic deletion, however, is not a practical option for patients, so the team next turned to pharmacology. They administered a soluble activin type IIB receptor fused to a human IgG1 Fc fragment, a decoy receptor that sequesters both myostatin and activin A in the circulation, by intraperitoneal injection twice weekly at a dose of 5 milligrams per kilogram. Four-week-old mutant mice received the treatment for four consecutive weeks. The intervention produced a marked anabolic effect: tibialis anterior mass was partially restored, quadriceps mass was completely normalized, and gastrocnemius mass actually exceeded wild-type values by the end of treatment. Serum myostatin concentrations rose during therapy, consistent with the decoy receptor prolonging the circulating half-life of the bound hormone and with increased production from newly expanded muscle mass.

But the pharmacological results came with two sobering caveats. First, the muscle gains proved entirely reversible: five weeks after treatment stopped, muscle mass had fallen back to untreated disease levels, indicating that continuous administration would be required to maintain any benefit. Second, and perhaps more importantly, the drug restored size without restoring power. In situ force measurements of the tibialis anterior showed no improvement in maximal absolute or specific force despite the hypertrophy. Molecular analysis explained why: while Akt Ser473 phosphorylation increased, confirming an anabolic signal, the treatment failed to correct the core pathological features of the disease, including elevated E3 ligase expression, impaired autophagic flux, reduced ribosomal and myosin heavy chain transcripts, and dysregulated expression of excitation-contraction coupling genes such as Chrna1, RyR1 and Casq1. Because dynamin 2 is known to organize transverse tubules, the membrane invaginations that transmit electrical signals deep into the fibre, these contractile defects appear intrinsic to the disease and beyond the reach of simply growing bigger fibres.

The contrast between the two strategies carries a clear message for the field. In mice, permanent myostatin inactivation reshapes developmental programs and delivers lasting improvements in both mass and function, whereas transient pharmacological blockade produces short-lived hypertrophy that leaves the underlying contractile and metabolic defects untouched. The authors note that combined myostatin and activin A inhibition may hold particular promise for human medicine, since activin A circulates at higher levels in people than in mice and signals through the same SMAD2/3 axis. Their conclusion is that future therapies for autosomal dominant centronuclear myopathy should be judged not merely by their ability to bulk up muscle, but by whether they durably restore contractile performance, likely in combination with approaches that directly repair the excitation-contraction machinery. The work was supported by AFM-Téléthon through the strategic MyoNeurALP programme.

Subject of Research: Myostatin inhibition therapy for dynamin 2-related centronuclear myopathy

Article Title: Genetic and Pharmacologic Inhibition of Myostatin Restores Muscle Mass in a Dynamin 2‐Related Centronuclear Myopathy Mouse Model

Article References: Anne‐Cécile, D., David, A., Mathias, V., Valentine, A., Chloé, P., Quentin, D., Esra, K., Sidney, C., Emmanuelle, G., Louise, C., Alexandre, G., Josiane, C., Aja, P., Maximilien, B., Baptiste, M., Christophe, H., Schaeffer, L., Olli, R., Marc, B., … Damien, F. (2026). Genetic and Pharmacologic Inhibition of Myostatin Restores Muscle Mass in a Dynamin 2 ‐Related Centronuclear Myopathy Mouse Model. Journal of Cachexia, Sarcopenia and Muscle, 17(5), Article e70338. https://doi.org/10.1002/jcsm.70338

Image Credits: AI Generated

DOI: 10.1002/jcsm.70338

Keywords: centronuclear myopathy, myostatin, dynamin 2, sActRIIB-Fc, muscle mass, muscle force, satellite cells, autophagy, excitation-contraction coupling, mouse model, neuromuscular disease, Akt signalling

The central insight of the review is a distinction between deficits within a phase and deficits at the transitions between phases. Aged skeletal muscle is impaired at every stage of post-injury repair that researchers have examined: immune cell recruitment is delayed and skewed in composition, the degradation of damaged debris lags behind its uptake, and muscle stem cells follow a broadly conserved activation trajectory but on delayed kinetics. Yet these within-phase problems may be differences of degree that a longer repair window can absorb. Transitions between phases offer no such slack. Each transition is triggered by a defined molecular switch, and if a compartment arrives late, it encounters a microenvironment already committed to a self-maintaining alternative state that its later output may be unable to reverse.

Three such switches anchor the repair sequence. The first is the fall in damage-related input that follows complete degradation of necrotic debris, which permits inflammation to begin resolving. The second is the balance between the inflammatory signal TNF and the profibrotic signal TGF-beta, which determines whether fibro-adipogenic progenitors, the stromal cells that temporarily support regeneration, undergo apoptosis and are cleared once their support phase ends. The third is the conversion of inflammatory Ly6C-high monocytes into reparative Ly6C-low macrophages, the immune pivot on which the shift from destruction to reconstruction depends. Because positive feedback loops operate beyond each of these switches, a lagging compartment does not simply slow the program; it can meet a tissue state that actively resists correction.

The review singles out retained mitochondrial lesions in postmitotic myofibers as one proposed input that can hold the first switch open. Skeletal muscle fibers are long-lived and cannot divide, so damaged mitochondrial DNA deletion mutations accumulate within individual fibers over decades, sometimes reaching detrimental levels intracellularly. These lesions can release mitochondrial DNA into the cytosol, where it activates the cGAS-STING innate immune pathway, a circuit that normally detects microbial DNA but misfires on self DNA. Mitophagy, the cellular quality-control system that normally removes damaged mitochondria, curtails this inflammatory activation in youth, but its capacity declines with age. The result is a persistent damage signal that keeps the injury phase of repair nominally alive even after the original wound has been cleared.

Meanwhile, the muscle stem cells themselves, the satellite cells that are absolutely required for regeneration, face a compounding set of problems. Their pool contracts with age, their fate allocation becomes skewed away from self-renewal, and they acquire cell-autonomous defects, including p38 MAPK-driven loss of self-renewal and p16- and p21-associated senescence, that persist even when aged cells are transplanted into a young host environment. Age-associated epigenetic changes can suppress genes such as SPRY1, causing stem cells to fail to return to quiescence and depleting the reserve pool needed for future injuries. The aged niche compounds this, with loss of fibronectin and WISP1 from fibro-adipogenic progenitors and stiffening of the extracellular matrix further degrading stem cell support.

The stromal compartment tells an equally troubling story. Fibro-adipogenic progenitors are essential early: they facilitate myogenesis, secrete supportive matrix proteins, and in youth are duly removed by TNF-triggered apoptosis once their job is done. In aged muscle, they resist clearance past their useful window, while the matrix around them stiffens and keeps pushing them toward a fibrogenic identity. Mechanotransduction studies show that substrate stiffness alone can drive progenitors into myofibroblasts, creating a feed-forward loop in which fibrosis begets more fibrosis. The same mechanical logic has been implicated in idiopathic pulmonary fibrosis, and the review argues that aged muscle may trap itself in an analogous self-reinforcing state from which no single late intervention can easily extract it.

The immune system completes the picture of desynchronization. Aged myeloid cells reach the pro-repair switch late and with attenuated output. Recruitment of inflammatory monocytes is delayed, their conversion to Ly6C-low reparative macrophages is blunted, and debris degradation lags behind phagocytic uptake, meaning material is swallowed but not fully digested. Regulatory T cells, which accumulate in injured muscle and potentiate repair through interleukin-33-dependent mechanisms, fail to accumulate properly in aged animals. The consequence is that when reparative macrophages and stem cells finally engage, the microenvironment has often already tipped toward chronic inflammation and matrix deposition, states maintained by their own positive feedback.

Crucially, the authors argue that none of these individual lesions need be the primary cause for the sequence to fail. This reframing has practical consequences for how regenerative interventions in aging should be judged. Rather than asking whether a therapy rescues one cell type in isolation, the review proposes evaluation against system-level criteria: does inflammation decline, does matrix remodeling close, does myogenic output yield mature fibers, and does the reserve stem cell pool survive repeated injury? Interventions that look promising in single-cell assays but leave transition timing intact failure would be expected to underperform, whereas approaches that restore coordination, even partially, may yield disproportionate benefit.

The framing also connects to a broader view of aging itself. Rather than a simple accumulation of damage in individual cells, aging here emerges as a systems-level breakdown in when things happen, not merely whether they happen. Sub-threshold delays, each individually tolerable, accumulate between compartments that must act in precise sequence, until one failed transition settles the tissue into an inflammatory-fibrotic endpoint that behaves like an alternative stable state. If this view is correct, future therapies for sarcopenia and poor healing in the elderly may need to target timing itself, restoring the ordered handoffs between macrophages, fibro-adipogenic progenitors, and stem cells, rather than simply boosting any one of them. The review, published as Volume 27, article 154 of Biogerontology, offers a conceptual scaffold for that next generation of studies.

Subject of Research: Temporal coordination failure, or phase-transition failure, in regeneration of aged skeletal muscle

Article Title: Phase-transition failure in aged skeletal muscle regeneration

Article References: Zhang, B., Shi, H., Guo, X., & Wang, Y. (2026). Phase-transition failure in aged skeletal muscle regeneration. Biogerontology, 27(5), Article 154. https://doi.org/10.1007/s10522-026-10500-6

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10500-6

Keywords: skeletal muscle, aging, regeneration, muscle stem cells, satellite cells, macrophages, fibro-adipogenic progenitors, inflammation, fibrosis, mitochondrial DNA, cGAS-STING, sarcopenia

The research team, led by Jing Pan and Tzu-Shao Yeh of the Department of Nutrition and Food Hygiene at Nantong University in China, together with Luthfia Dewi of Universitas Muhammadiyah Semarang in Indonesia, focused their experiments on C2C12 cells, a widely used mouse skeletal muscle cell line that recapitulates key stages of muscle formation. These cells can be induced to behave like satellite cells, the resident stem cells of skeletal muscle, and to progress through the full differentiation program that turns undifferentiated myoblasts into mature, multinucleated myotubes, the cellular equivalent of muscle fibers. By treating these cells with boswellic acid and measuring changes at both the RNA and protein levels, the investigators were able to map the compound’s effects across the entire myogenic cascade.

The results were striking at multiple points along this cascade. Boswellic acid treatment produced a 17 percent increase in the number of Pax7-positive cells. Pax7 is the canonical marker of satellite cell identity and quiescent muscle stemness, and an expanded Pax7-positive population suggests that the compound preserves or expands the pool of cells capable of regenerating damaged or aging muscle tissue. This is a critical finding for the muscle aging field, because one hallmark of aged muscle is the depletion and dysfunction of its satellite cell reserve, leaving old muscles increasingly unable to repair themselves after injury, disuse, or disease.

Beyond stemness, the compound appeared to push cells more rapidly through the commitment and differentiation stages of muscle formation. The researchers quantified the relative messenger RNA levels of four master regulators of myogenesis: Pax7, Myf5, MyoD, and MyoG. These myogenic regulatory factors act in a choreographed sequence, with Pax7 maintaining the stem cell state, Myf5 and MyoD committing cells to the muscle lineage, and myogenin driving terminal differentiation and fusion into myotubes. Following boswellic acid treatment, the mRNA and protein levels of Myf5, MyoD, and MyoG were all significantly upregulated, indicating that the treated cells were accelerating through the myogenic differentiation program. The study also documented a two to four hour advancement in the myoblast renewal cycle, suggesting that the compound speeds the temporal rhythm by which muscle precursor cells proliferate and renew themselves before differentiating.

Protein-level confirmation came from Western blotting, a technique that separates proteins by molecular weight and detects them with specific antibodies. The team measured protein expression of Pax7, Myf5, MyoD, and MyoG, alongside loading controls such as beta-actin and GAPDH, and found the upregulation observed at the RNA level faithfully mirrored at the protein level. Immunofluorescence staining was used to visualize Pax7 and MyoD expression within individual cells, providing spatial confirmation that the molecular changes translated into shifts in the cellular populations themselves. Cell viability was assessed with the XTT assay, ensuring that the observed pro-myogenic effects were not simply an artifact of compound toxicity or stress-induced changes in cell behavior.

Perhaps the most translationally intriguing results concern hypertrophy, the enlargement of existing muscle fibers. Boswellic acid treatment significantly enhanced myotube hypertrophy through activation of the canonical hypertrophic signaling axis: the Akt-mTOR-p70S6K pathway. This pathway is the central growth-control circuit of skeletal muscle, integrating signals from insulin-like growth factor 1, mechanical loading, and nutrient availability to drive protein synthesis. Akt, or protein kinase B, phosphorylates and regulates downstream targets including mTOR, the mammalian target of rapamycin, which in turn activates p70S6K, a ribosomal protein S6 kinase that promotes ribosomal biogenesis and translation of muscle proteins. The researchers observed increased phosphorylation of all three nodes, indicating that boswellic acid switches on the same anabolic program engaged by resistance exercise and IGF-1 signaling.

The convergence of two effects, expanded stem cell activity and heightened anabolic signaling, is what distinguishes this study from many single-mechanism nutraceutical investigations. Aging muscle fails on both fronts: satellite cells become less numerous and less responsive, and the Akt-mTOR axis becomes progressively resistant to the anabolic stimuli of food intake and exercise, a phenomenon sometimes called anabolic resistance. A compound that simultaneously supports the regenerative stem cell compartment and re-energizes protein synthesis signaling could, in principle, address both dimensions of sarcopenia. The authors suggest that boswellic acid warrants consideration as a nutraceutical agent to enhance muscle differentiation and hypertrophy, and as a potential novel therapeutic strategy for mitigating muscle aging.

Boswellic acid itself has a long pharmacological history. It is the principal bioactive component of frankincense, the resin of Boswellia serrata and related species, and has been studied extensively for its anti-inflammatory properties, particularly its inhibition of 5-lipoxygenase and its effects on inflammatory pathways relevant to arthritis and inflammatory bowel disease. This new study extends its potential repertoire into muscle biology, a domain more commonly occupied by compounds such as creatine, leucine, and other branched-chain amino acids, and by pharmaceutical agents under development for sarcopenia. The triterpenoid structure of boswellic acid allows it to interact with multiple signaling proteins, which may explain its pleiotropic effects across the myogenic program and the growth-factor cascade.

The authors are careful to frame the work within its in vitro limits. All experiments were conducted in murine cell cultures, and the physiological concentration, absorption, and tissue distribution of boswellic acid in living organisms remain open questions. Satellite cell behavior in aged muscle is shaped by a complex niche of inflammatory signals, extracellular matrix changes, and vascular decline that a simplified cell culture cannot fully reproduce. The researchers explicitly state that additional in vivo and clinical investigations are warranted before any therapeutic relevance can be established. Human trials would need to establish safe dosing, bioavailability, and whether oral supplementation can achieve tissue concentrations capable of activating the pathways observed in culture.

Even so, the study adds to a growing scientific effort to identify accessible dietary compounds that can bias the balance between muscle loss and muscle regeneration in favor of renewal. With sarcopenia estimated to affect a substantial share of adults over sixty and to drive frailty, falls, and loss of independence, the search for safe, well-tolerated interventions is intensifying. If future animal and human studies confirm the mechanisms reported here, boswellic acid, a molecule that humans have consumed for millennia in the form of frankincense, could emerge as an unusually well-characterized candidate for supporting muscle health across the lifespan. For now, the finding stands as a compelling proof of concept: an ancient resin component, examined with modern molecular tools, appears capable of speaking the native language of regenerating muscle.

Subject of Research: Effects of boswellic acid on myogenic and hypertrophic signaling in skeletal muscle cells as a potential strategy against muscle aging

Article Title: Boswellic acid modulates myogenic and hypertrophic signaling in vitro: implications for muscle aging

Article References: Pan, J., Dewi, L., & Yeh, T.-S. (2026). Boswellic acid modulates myogenic and hypertrophic signaling in vitro: implications for muscle aging. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05596-9

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05596-9

Keywords: boswellic acid, satellite cells, sarcopenia, muscle aging, myogenesis, skeletal muscle hypertrophy, Akt-mTOR-p70S6K, myogenic regulatory factors, nutraceutical, C2C12 cells, muscle regeneration, frankincense

Eccentric exercise occurs when a muscle lengthens under load, as it does when lowering a weight or running downhill, generating high mechanical tension at a comparatively low metabolic cost. Concentric exercise, by contrast, shortens the muscle under load, as in uphill running or lifting. Physiotherapists and sports physicians have long observed that eccentric training builds strength efficiently and reduces the incidence of hamstring injuries by as much as 56.8 to 70 percent in some reported cohorts, yet the underlying mechanism linking this unique stress profile to enhanced tissue repair has remained elusive. The new research, conducted in mice using a barium chloride-induced injury model that reproducibly triggers myofibre necrosis while preserving the satellite cell niche, set out to close that gap.

The team subjected injured mice to five days of treadmill running, with one group performing downhill running at a minus 15-degree incline to simulate eccentric exercise and another performing uphill running at plus 15 degrees to simulate concentric exercise. Seven days after injury, the downhill-running animals displayed markedly better organised regenerating tissue in the tibialis anterior muscle, less collagen Iα deposition, and elevated expression of the myogenic regulators Myod, Myog and embryonic myosin heavy chain. Immunofluorescence revealed more newly formed eMyhc-positive fibres, and the extensor digitorum longus muscles of the eccentric group generated greater maximal tetanic force. In short, eccentric contraction was the more effective healer.

To explain the difference, the researchers turned to extracellular vesicles, nanoscale particles typically ranging from roughly 50 to 150 nanometres that cells release to ferry proteins, lipids, RNAs and metabolites between cells. Skeletal muscle is known to shed these vesicles during exercise, and the team hypothesised that the two contraction modes might load them differently. Western blotting showed that Rab27a, a key regulator of vesicle secretion, was more strongly expressed after eccentric exercise, and ex vivo experiments using the Aurora Scientific 1200A system confirmed that isolated soleus, extensor digitorum longus and tibialis anterior muscles secreted more vesicles during eccentric than concentric contractions. Transmission electron microscopy and nanoparticle tracking analysis characterised the vesicles, while canonical markers such as CD63, ALIX, TSG101 and CD9 were elevated in the eccentric group.

The causal evidence was compelling. When the researchers blocked vesicle production with GW4869, an inhibitor of vesicle biogenesis, the benefits of eccentric exercise largely vanished: regenerating muscles showed disorganised morphology, increased fibrosis, reduced myogenic marker expression and fewer newborn fibres. Conversely, when vesicles harvested from the muscles of exercised mice were injected directly into injured muscles, the vesicles entered satellite cells, as demonstrated by PKH26 labelling, and accelerated repair. Critically, vesicles from eccentrically exercised donors outperformed those from concentric donors and sedentary controls, producing better tissue architecture, less collagen deposition, higher Myog protein and more eMyhc-positive regenerating fibres.

What made the eccentric vesicles so potent? The answer appears to lie in their cargo. Non-targeted metabolomic profiling using liquid chromatography-mass spectrometry revealed that lipid metabolites, particularly phosphatidylcholines and sphingomyelins, were the most enriched class of upregulated molecules in vesicles from eccentrically exercised muscle. Quantitative PCR showed corresponding upregulation of lipid metabolism genes, and KEGG pathway analysis confirmed that lipid metabolism was significantly more active in the eccentric vesicles. Because phosphatidylcholines supply substrates for membrane remodelling, a process essential for myoblast fusion and fibre growth, while sphingomyelins populate lipid rafts that organise pro-differentiation signalling, the authors propose that these lipids act as both building blocks and signals for regeneration.

Functional tests strengthened the case. When the researchers blocked lipid metabolism in exercising muscle using BMS-309403, an inhibitor of the fatty acid binding protein AP2, vesicles extracted from those muscles lost nearly all of their regenerative advantage, both in injured mice and in cultures of C2C12 myoblasts. Supplementation experiments with PI (18:1/18:1), a phosphatidylinositol species highly enriched in eccentric vesicles, activated the energy-sensing AMPK pathway, boosted MyoD expression and rescued the pro-myogenic capacity of otherwise weaker vesicle preparations, while the AMPK inhibitor Compound C attenuated these effects. Vesicles from eccentric exercise also raised ATP levels and mitochondrial membrane potential in recipient cells.

Transcriptomics added a further layer of mechanism. RNA sequencing of myoblasts treated with the different vesicle populations showed activation of fatty acid metabolism pathways and a stepwise, exercise-dependent increase in nine genes, including Prkag3, a known supporter of muscle repair, and the mitochondrial energy-sensing genes Cox7a1, Cox6a2 and Cox8b. Together with the metabolomic and pharmacological data, the picture that emerges is of vesicles acting as lipid-rich metabolic packages that reprogramme satellite cells and myoblasts toward an energetically primed, differentiation-ready state, thereby accelerating the reconstruction of damaged tissue.

The therapeutic implications are considerable, particularly for patients who cannot exercise after injury. Because improper eccentric training can itself cause secondary muscle damage, the prospect of isolating or mimicking the vesicles released during downhill running, and administering them exogenously, offers a way to capture the regenerative benefits of exercise without the movement that injured limbs may not tolerate. The authors caution that significant hurdles remain before clinical translation, including scalable production with consistent quality, batch-to-batch variability, maintaining vesicle stability during storage, achieving targeted delivery to injured muscle, and excluding immunogenicity or long-term adverse effects. The study also used only male mice, leaving open whether the findings extend to females, and other exercise-induced factors beyond vesicles may contribute to regeneration. Nevertheless, by demonstrating that the healing power of eccentric contraction travels, at least in part, inside lipid-laden extracellular vesicles, the work transforms these nanoscale particles from a curiosity of intercellular communication into a promising natural therapeutic candidate, one that could eventually shorten recovery times for athletes and patients alike and reshape rehabilitation medicine around the molecular conversation that exercising muscles hold with their own stem cells.

Subject of Research: Muscle-derived extracellular vesicles released during eccentric exercise that promote skeletal muscle regeneration after injury

Article Title: Skeletal Muscle–Derived Extracellular Vesicles During Eccentric and Concentric Exercise Promote Muscle Regeneration After Injury

Article References: Zhou, Y., Shao, X., Zhang, P., Lin, J., Chen, X., An, X., Jiang, Z., Wang, H., Fang, D., Xian, Y., Liu, B., Shen, T., Chen, Y., Li, K., Liu, H., Li, Y., Jiang, Q., & Guo, B. (2026). Skeletal Muscle–Derived Extracellular Vesicles During Eccentric and Concentric Exercise Promote Muscle Regeneration After Injury. Journal of Cachexia, Sarcopenia and Muscle, 17(5), Article e70374. https://doi.org/10.1002/jcsm.70374

Image Credits: AI Generated

DOI: 10.1002/jcsm.70374

Keywords: extracellular vesicles, eccentric exercise, concentric exercise, skeletal muscle regeneration, satellite cells, lipid metabolites, myokines, muscle injury, metabolomics, AMPK signalling, myoblast differentiation, rehabilitation